Helios Mass Cytometer

项目总结 山上的伊坎医学院西奈正在申请资金购买赫利俄斯弥撒 由Fluidigm Inc.制造的细胞仪，用于促进基础、翻译和临床研究 发现号。质量细胞术是一项融合了高通量单细胞的前沿技术 用质谱仪的特异性和分辨率分析流式细胞术；抗体 结合到纯化的稀土金属同位素被用来标记复杂的细胞混合物，这些细胞是 然后用飞行时间质谱仪进行分析。通过克服荧光光谱的局限性 排放，这允许超过40个参数(未来试剂有可能超过100个 发展)在单个细胞的基础上同时测量，从而允许更深层次的 异质细胞样本的表型和功能图谱，以产生对 疾病进展和治疗反应的生物过程和新的生物标记物。 虽然质量细胞术为科学发现提供了巨大的潜力，但一些主要的 成功建立这项技术的挑战包括需要专门的基础设施， 技术和科学专长、试剂和方案以及计算资源。Mt.Mt.西奈半岛 2013年获得第二代CyTOF2质量细胞仪，并已成功 克服所有这些挑战，建立高效的全方位服务质量细胞分析计划，如 人类免疫监测核心的一部分，目前由美国国立卫生研究院资助的50多家机构使用 调查人员。这一应用的动力是我们目前的仪器得到了最大限度的利用， 我们需要另一台仪器来满足我们科学和技术人员日益增长的质量细胞分析需求 临床社区。通过在必要的基础设施和试剂上投入巨资， 并建立了与质量细胞学相关的深厚的科学、技术、计算专业知识，我们可以 确保Helios质量细胞仪的顺利和成功集成，并最大限度地发挥其对 Mt.Mt.西奈的翻译和临床研究工作。

Project summary The Icahn School of Medicine at Mt. Sinai is requesting funds for the purchase of a Helios Mass Cytometer, manufactured by Fluidigm Inc., to facilitate basic, translation and clinical research discovery. Mass cytometry is a cutting edge technology that merges the high-throughput single cell analysis of flow cytometry with the specificity and resolution of mass spectrometry; antibodies conjugated to purified rare-earth metal isotopes are used to label complex mixtures of cells, which are then analyzed by time-of-flight mass spectrometry. By overcoming the limitations of fluorescent spectral emission, this allows over forty parameters (with the potential for over 100 with future reagent development) to be simultaneously measured on a single cell basis, thereby allowing deeper phenotypic and functional profiling of heterogeneous cell samples to yield mechanistic insights into biological processes and novel biomarkers of disease progression and responses to therapy. While mass cytometry offers tremendous potential for scientific discovery, some of the major challenges in successfully establishing this technology include the need for specialized infrastructure, technical and scientific expertise, reagents and protocols, and computational resources. Mt. Sinai acquired a second-generation CyTOF2 mass cytometry in 2013 and has already successfully overcome all these challenges to establish a highly-productive full-service mass cytometry program as part of the Human Immune Monitoring Core, which is currently utilized by over 50 NIH-funded investigators. The impetus for this application is that our current instrumentation is utilized at capacity, and we require a second instrument to meet the growing mass cytometry needs of our scientific and clinical community. By having already heavily invested in the necessary infrastructure and reagents, and established deep scientific, technical, computational expertise related to mass cytometry, we can assure the smooth and successful integration of a Helios mass cytometer and maximize its impact on Mt. Sinai's translational and clinical research efforts.